Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

The Italian said it has banned the sale and use of several flu vaccines produced by Novartis pending tests into possible side-effects.

"The health ministry and the Italian medicines agency (AIFA) have decided to take the precaution of banning immediately the use of the vaccines" Aggripal, Fluad and Influpozzi, it said.

On the basis of information supplied by Novartis, AIFA "has decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines, which "can produce collateral effects," the statement said.

In Switzerland, the national drug agency Swissmedic said it was ordering the "immediate halt of deliveries from Novartis," due to "possible ".

The alarm was raised after white particles were seen in syringes carrying the vaccines, Swissmedic said, stressing that they could be nothing more than little of the vaccine's components.

The Swiss decision affects some 160,000 , Swissmedic said, adding that it was unclear whether the problem affected vaccines already available in Switzerland.

The freeze on sales of the vaccines and their use was "a simple precaution" and those who had already been vaccinated for the flu "had nothing to worry about", it added.

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following the moves by Italy and Switzerland.

stu-ide-nl/har

In their statement explaining the freeze on vaccine imports, Italian authorities said they had "decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines.

burs/har

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following similar decisions by Italy and Switzerland.

add to favorites email to friend print save as pdf

Related Stories

Novartis denies problems with swine flu vaccine

Oct 26, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

New development could increase flu vaccine supply

Jun 02, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or com ...

Novartis starts testing swine flu vaccine

Aug 05, 2009

(AP) -- Swiss drugmaker Novartis has begun injecting its swine flu vaccine into people in the company's first human tests, a spokesman said Wednesday. The vaccine is being tested in a yearlong trial of 6,000 ...

EU drug agency: License 2 swine flu vaccines

Sep 25, 2009

(AP) -- The European Union's drug regulator recommended Friday that two swine flu vaccines be licensed in the 27-nation bloc to ensure their availability before the start of the normal flu season.

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments